|  | Conditions & Treatments | Chronic Fatigue Syndrome

HRT During Menopause: Weighing Pros & Cons – Doctor-Approved Guide

Hormone Replacement Therapy (HRT)—now often called Menopausal Hormone Therapy (MHT)—is the most effective treatment for vasomotor symptoms (hot flashes, night sweats) and genitourinary syndrome of menopause (GSM). The decision is personal, nuanced, and revisitable.

What HRT Treats Best

  • Vasomotor symptoms (VMS): 75–90% reduction in frequency/severity.
  • GSM: Vaginal dryness, dyspareunia, urinary urgency, recurrent UTIs — local estrogen (cream, ring, tablet) is first-line, minimal systemic absorption.
  • Bone: Prevents postmenopausal bone loss, reduces fracture risk (while on it).
  • Mood/sleep: Secondary benefit for many.

Risk-Benefit Landscape (WHI & Post-WHI Evidence)

OutcomeEstrogen + Progestin (E+P)Estrogen Alone (ET) (hysterectomy)
Invasive Breast Cancer↑ Risk (RR ~1.24) after 3–5 yrs use↓ Risk (RR ~0.77) in WHI
Stroke↑ Risk (RR ~1.3)↑ Risk (RR ~1.4)
Venous Thromboembolism (VTE)↑ Risk (RR ~2.0) — oral route↑ Risk (RR ~1.3) — oral
Coronary Heart DiseaseNeutral/↑ if started >10 yrs post-menopause / age >60Neutral/↓ if started <10 yrs / age <60 ("Timing Hypothesis")
Dementia↑ Risk if started >65↑ Risk if started >65
All-cause MortalityNeutralNeutral/↓

Key Modifiers of Risk

  • Age / Time since menopause: Start <60 and/or <10 yrs post-menopause = favorable window. "Timing hypothesis" supported by multiple studies.
  • Route: Transdermal (patch, gel, spray) avoids first-pass hepatic effect → lower VTE, stroke, triglyceride impact. Preferred for metabolic/cardiovascular risk factors.
  • Progestin type: Micronized progesterone (bioidentical) → better breast, cardiovascular, metabolic profile vs. synthetic (MPA, norethindrone).
  • Dose: Lowest effective dose. Modern regimens: 0.025–0.05 mg/day transdermal E2; 100–200 mg micronized progesterone.
  • Duration: Individualized. No arbitrary "5-year limit." Annual reassessment.

Contraindications (Relative/Absolute)

  • Active VTE, stroke, MI, uncontrolled HTN
  • Estrogen-sensitive cancer (breast, endometrial) — oncology clearance required
  • Active liver disease
  • Unexplained vaginal bleeding
  • Pregnancy

Non-Hormonal Alternatives

  • VMS: Fezolinetant (NK3 antagonist, FDA 2023), Gabapentin, Oxybutynin, SSRIs/SNRIs (paroxetine low-dose, venlafaxine), CBT, clinical hypnosis.
  • GSM: Vaginal moisturizers (Replens), lubricants, ospemifene (SERM), vaginal DHEA (prasterone), laser/radiofrequency (limited evidence).
  • Bone: Bisphosphonates, denosumab, anabolics.
  • Lifestyle: Resistance training, Mediterranean diet, sleep, stress mastery, smoking cessation.

Discontinuation

Taper over 3–6 months (e.g., halve dose q4–8 wks) to minimize rebound VMS. Can restart if symptoms return. Local estrogen can continue indefinitely.

Decision Framework

  1. Symptom severity + quality-of-life impact.
  2. Personal/family history (breast cancer, VTE, CVD, stroke, dementia).
  3. Age, years since menopause.
  4. Route, formulation, dose preferences.
  5. Values: symptom relief vs. risk tolerance.

HRT/MHT is neither poison nor panacea. It's a tool—powerful when matched to the right woman, at the right time, in the right form.

Chronic Fatigue Syndrome - Related Articles